ロード中...
Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease pre...
保存先:
| 出版年: | J Infect Dis |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7347079/ https://ncbi.nlm.nih.gov/pubmed/32645161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiaa098 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|